Treatment of chronic heart failure.
Packer
M
M
Division of Circulatory Physiology, Columbia University, College of Physicians and Surgeons, New York, NY 10032.
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D002316:Cardiotonic Agents / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use; D002317:Cardiovascular Agents / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use*; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004232:Diuretics / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D009490:Neurosecretory Systems / Q000187:drug effects*; D014665:Vasodilator Agents / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D002316:Cardiotonic Agents; D002317:Cardiovascular Agents; D004232:Diuretics; D014665:Vasodilator Agents